Skip to content
The World Health Organization (WHO) suggests additional waivers of intellectual property rights during the next pandemic in the initial draft of its global pandemic […]
Draft WHO pandemic treaty suggests future IP waivers Read More »
The intellectual property protections that enabled the record-setting development of COVID-19 vaccines and treatments require rigorous federal protection, says the Biotechnology Innovation Organization (BIO)
BIO recommends 11 countries for USTR’s Priority Watch List Read More »
In a move that will help the 340B pharmaceutical discount program get back on track, the U.S. Third Circuit Court of Appeals decided Monday
Federal court rules against HHS on 340B contract pharmacies Read More »
Yesterday, the Biotechnology Innovation Organization’s (BIO) Clinical Trial Diversity Roundtable brought together leaders from government, industry, and patient groups to begin implementing the clinical
BIO roundtable works toward greater clinical trial diversity Read More »
A significant date for biotechnology and the historic fight to create vaccines, the Biden administration will end the COVID-19 public health emergency on May
U.S. COVID public health emergency will end in May Read More »
Acting upon the Food and Drug Administration’s (FDA) request, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) decided unanimously on Thursday to
VRBPAC recommends harmonizing COVID vaccines content Read More »
Ahead of the U.S. Food and Drug Administration’s (FDA) meeting to discuss the nation’s COVID-19 vaccine strategy, two studies published Wednesday provide more evidence
Bivalent boosters halve infection, hospitalization risk of XBB variants, studies show Read More »
Australian scientists are a step closer to finding new and more effective treatments for lymphoma and lung cancer after opening up new treatment options
Australian scientists work on helping the immune system kill cancer cells Read More »
Over the last 10 years, partnering has been an essential driver of the U.S. biotech business, with external partnerships increasing by 152% and tripling
Partnering is a big deal at the BIO CEO & Investor Conference in NYC, Feb. 6-7 Read More »
In light of the drastic rebate hike prompted by inflation and COVID-driven increases in demand, the U.K. is no longer a viable market for
European lessons on drug price controls teach the U.S. how ‘not to do it’ Read More »
